ArticleNPJ breast cancer2021

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.

Jamunarani Veeraraghavan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.